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Abstract. The role of the latent TGF-[3 binding protein 
(LTBP) is unclear. In cultures of fetal rat calvarial cells, 
which form mineralized bonelike nodules, both LTBP 
and the TGF-[31 precursor localized to large fibrillar 
structures in the extracellular matrix. The appearance 
of these fibrillar structures preceded the appearance of 
type I collagen fibers. Plasmin treatment abolished the 
fibrillar staining pattern for LTBP and released a com- 
plex containing both LTBP and TGF-[3. Antibodies and 
antisense oligonucleotides against LTBP inhibited the 
formation of mineralized bonelike nodules in long-term 
fetal rat calvarial cultures. Immunohistochemistry of fe- 
tal and adult rat bone confirmed a fibrillar staining pat- 
tern for LTBP in vivo. These findings, together with the 
known homology of LTBP to the fibrillin family of pro- 
teins, suggest a novel function for LTBP, in addition to 
its role in matrix storage of latent TGF-~, as a structural 
matrix protein that may play a role in bone formation. 
T  GF-13 is secreted by virtually all cells in one or more 
latent forms that are biologically inert (Miyazono et 
al.,  1988; Wakefield et al., 1988). Most cells secrete 
TGF-[3 as  a  290-kD  high  molecular mass  latent  TGF-13 
complex that contains a 190-kD latent TGF-[3 binding pro- 
tein (LTBP)  1 linked by a disulfide bridge to the TGF-131 
precursor (also known as latency-associated peptide) (see 
Fig. 1) (Kanzaki et al., 1990; Tsuji et al., 1990). Platelets se- 
crete a  latent complex with a  130-kD  truncated form of 
LTBP. We have shown previously that osteosarcoma cells 
and bone organ cultures secrete at least three forms of la- 
tent  TGF-[3, including  the  290-kD  high  molecular mass 
form (Bonewald et al., 1991; Dallas et al., 1994). However, 
bone cells are unique in that at least 50%  of their latent 
TGF-13 is secreted as a  100-kD latent complex that lacks 
LTBP and consists only of the mature 25-kD TGF-[3 ho- 
modimer noncovalently associated with a  70-kD portion 
of the precursor homodimer. 
Mature (or active) TGF-[3 exerts effects in a variety of 
cell types. These can be broadly grouped into effects on 
matrix formation, inhibition of cell growth, and immuno- 
suppression  (for reviews  see  Roberts  and  Sporn,  1990; 
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1. Abbreviation used in this paper: LTBP, latent TGF-13 binding protein. 
Border  and  Ruoslahti,  1992;  Sporn  and  Roberts,  1992; 
Bonewald and Dallas, 1994; Centrella et al., 1994). Whereas 
many activities have been ascribed to active TGF-[3, the 
functions of the different latent TGF-[3 complexes are less 
clear. In particular, the function of the latent TGF-[3 bind- 
ing protein has not yet been defined. Although it was as- 
sumed initially to confer latency to the TGF-13 complex, it 
is  now  known  that  the  100-kD  precursor  complex that 
lacks LTBP is also latent, indicating that LTBP is not es- 
sential for latency (Gentry et al.,  1987;  Bonewald et al., 
1991). LTBP appears to play a role in assembly and secre- 
tion of the latent TGF-13 complex in human erythroleuke- 
mia cells (Miyazono et al.,  1991). However, this does not 
seem to be the case in bone cells, where the 100-kD com- 
plex that lacks LTBP is efficiently secreted. Indeed, the rat 
osteosarcoma cell line UMR-106 secretes high amounts of 
latent TGF-13, and produces exclusively the 100-kD latent 
TGF-13 complex lacking LTBP (Dallas  et al.,  1994).  Al- 
though it has been shown that LTBP may facilitate activa- 
tion  of latent  TGF-13  in  co-cultures  of endothelial  and 
smooth muscle cells (Flaumenhaft et al., 1993), the possi- 
ble mechanism for this remains unclear. 
Sequence analysis of LTBP reveals a number of features 
characteristic of matrix or adhesion molecules, which in- 
clude 16 EGF-like repeats, an RGD sequence, a putative 
calcium-binding domain,  and  an eight-amino acid motif 
identical to the cell-binding domain of [32-1aminin (Kan- 
zaki et al.,  1990; Tsuji et al.,  1990). Several of these lea- 
© The Rockefeller University Press, 0021-9525/95/10/539/11  $2.00 
The Journal of Cell Biology, Volume 131, Number 2, October 1995 539-549  539 ined by Western blotting and immunohistochemistry. Fi- 
nally,  the  effect of addition  of antibodies  and  antisense 
oligonucleotides against LTBP was examined in long-term 
fetal  rat  calvarial  cell  cultures.  These  studies  show  that 
LTBP may be a  structural fibrillar-type extracellular ma- 
trix protein that plays an important role in the bone for- 
mation process. These findings may have implications for 
the  role  of  LTBP  in  normal  and  pathological  matrix 
formation in other tissues. 
Figure  1.  Schematic  diagram  showing latent  TGF-13  complexes 
that have been characterized in various cell types. The 100-kD re- 
combinant latent TGF-[3  complex consists of the mature  25-kD 
TGF-[3  homodimer noncovalently associated with a  70-kD  por- 
tion of the precursor homodimer (Gentry et al., 1987). Bone cells 
secrete ~50%  of their latent TGFq3  in a  similar 100-kD precur- 
sor form (Bonewald et al., 1990). Most other cell types produce a 
high  molecular  weight  latent  TGF-I3  complex  in  which a  third 
protein, the LTBP, is linked to the precursor by a  disulfide link- 
age (Miyazono et al., 1988; Wakefield et al., 1988; Kanzaki et al., 
1990; Tsuji et al., 1990). LTBP is 190 kD in fibroblasts and 130 kD 
in platelets, making latent TGF-13 complexes of 290 kD  and 230 
kD respectively. *, internal cleavage site. 
tures  are  shared  with  the  fibrillin family of extracellular 
matrix proteins  (Sakai  et  al.,  1986,  1991;  Maddox  et  al., 
1989;  Rosenbloom et al., 1993; Zhang et al., 1994).  LTBP 
also contains a novel eight-cysteine repeat motif unique to 
the fibrillin family. Protein studies have confirmed that a 
large amount of LTBP, a proportion of which has TGF-13 
associated with it, is found in the extracellular matrix of fi- 
broblasts (Taipale et al.,  1994).  We hypothesized that  in 
bone the 290-kD latent TGF-[3 complex containing LTBP 
targets latent TGF-[3 to bone matrix for storage, whereas 
the 100-kD form may be a secretory form, which is more 
readily  available  for  cellular  activation.  Consistent  with 
this hypothesis, Sato et al. (1993) have demonstrated that 
the 100-kD latent TGF-[3 is able to bind to the cell surface 
by an unknown mechanism. 
To  determine  whether  LTBP  could  target  the  latent 
TGF-13 complex for matrix storage in bone cells, we used 
fetal rat calvarial cell cultures as a  representative in vitro 
model of bone formation. These cells differentiate in vitro 
and form mineralized  nodules with the  characteristics of 
woven bone (Bellows et al., 1986; Harris et al., 1994).  Mor- 
phologically  distinct  stages  can  be  identified  during  the 
differentiation  process  (Dworetzky  et  al.,  1990).  In  this 
study  these  were  defined  as  the  proliferating  stage,  the 
early (confluent) stage, the middle stage, where multilay- 
ered cellular nodules are beginning to form and the extra- 
cellular matrix is maturing, and the late stage, where the 
cellular nodules have become mineralized. We performed 
immunocytochemistry for LTBP, TGF-131  precursor, and 
type I collagen in long-term fetal rat calvarial cell cultures 
to examine the  expression and possible colocalization of 
these molecules. LTBP was also localized in vivo by immu- 
nohistochemistry  in  frozen  sections  of long  bones  from 
young adult and fetal rats. We then determined the effect 
of plasmin digestion on the release of latent TGF-[3 com- 
plexes from the matrix of fetal rat calvarial cells as exam- 
Materials and Methods 
Materials 
Antibody against LTBP (Ab39) was a rabbit antiserum raised against na- 
tive LTBP purified from human platelets (Kanzaki et al., 1990). Antibody 
against  the  TGF-[31  precursor  (LT-2)  was  a  rabbit  antiserum  raised 
against recombinant TGF-[31  (Mizoi et al.,  1993).  Antibody against ma- 
ture TGF-[3 was a polyclonal rabbit antibody raised against porcine TGF- 
[31.2 obtained from R  &  D  Systems, Inc. (Minneapolis, MN). Antibody 
against rat  type I  collagen was a  rabbit polyclonal antiserum obtained 
from BIODESIGN  International  (Kennebunkport, ME).  Recombinant 
human LTBP was generously donated by K. Takemura  (Kirin Brewery 
Co. Ltd., Maebashi Gunma, Japan). Partially purified platelet latent TGF-[3 
complex was prepared in our laboratory as described previously (Bone- 
wald et al., 1991). Bovine plasmin was obtained from Sigma Chemical Co. 
(St. Louis, MO). Oligonucleotides were synthesized on a DNA/RNA syn- 
thesizer (Model 392; Applied Biosystems, Inc., Foster City, CA), and puri- 
fied using Poly Pak cartridges (Glen Research Corp., Sterling, VA) ac- 
cording to manufacturer's instructions. Sense and antisense nucleotides 
were made for the sequence GAGACTGCCCGCGATGG  of rat LTBP, 
which includes the translation start site (Tsuji et al., 1990). 
Fetal Rat Calvarial Cell Cultures 
Unless stated otherwise, all tissue culture reagents were purchased from 
Life Technologies Inc. (Gaithersburg, MD) or JRH Biosciences (Lenexa, 
KS). The isolation of fetal rat calvarial cells was performed as described 
previously (Harris et al., 1994), using a modification of the method of Bel- 
lows et al. (1986).  Briefly, frontal and parietal bones from ICR-Swiss rat 
fetuses (19-d gestation) were digested in 0.2% collagenase/0.05% trypsin 
in HBSS to obtain six sequential 20-min digests. The third through sixth 
digests were combined and grown to confluence in MEM, alpha modifica- 
tion (~-MEM) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin-streptomycin. At  confluence  the  cells  were  trypsinized  and 
plated for experiments at 10,000 cells/cm  2 growth area. Long-term miner- 
alizing fetal rat calvarial cell cultures were maintained in u-MEM supple- 
mented with 5% FBS, 2 mM L-glutamine, 100 U/ml penicillin-streptomy- 
cin,  5  mM  [3-glycerophosphate, and  100  ~g/ml L-ascorbic acid with or 
without test factors. Culture medium (including test factors) was changed 
every 3  d.  For sense and  antisense experiments, fresh oligonucleotides 
were added to the cultures every 24 h. 
For quantitation of mineralized nodules in the fetal rat calvarial cell 
cultures, the cultures were fixed in neutral buffered formalin and stained 
by  the Von Kossa method with Van  Gieson's picric acid-acid fuchsin 
counterstain (Harris et al.,  1994).  The number and area of Von Kossa- 
stained nodules was then quantified by automated image analysis using a 
video analysis program (Jandel Scientific, San Rafael, CA) linked up to a 
videoscreen camera (CCD/RGB; Sony Corp., Park Ridge, NJ) and micro- 
scope (BH2; Olympus Corp,, Precision Instruments Division, Lake Suc- 
cess, NY) equipped with metallurgical lenses. 
Immunocytochemistry 
Immunocytochemistry was performed on cells grown in chamber slides 
(Lab-tek; Nunc Inc., Naperville, IL). These preparations were fixed for 10 
min in 95% ethanol. Immunocytochemistry was also performed on frozen 
sections of bone from young-adult Wistar rats (body wts 85-150 g) and fe- 
tal rats (19-d gestation, ICR-Swiss). Frozen tissue sections were obtained 
as described previously (Skerry et al.,  1989). Briefly, fresh, undecalcified 
tissue was frozen by precipitate immersion in hexane cooled in a slurry 
bath of ethanol and dry ice. 8 txm cryostat sections were cut using a heavy- 
duty cryostat fitted with a tungsten carbide-edged blade (Bright Instru- 
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with Vectabond (Vector Laboratories, Burlingame, CA) and were then 
fixed in chilled acetone for 5 min before immunohistochemical  staining. 
Endogenous peroxidase activity was blocked by preincubation in 3% 
hydrogen peroxide in PBS for 30 min at room temperature. Background 
blocking was performed by incubating specimens in 1% normal goat se- 
rum in PBS for 3 h at room temperature. Specimens were incubated in pri- 
mary antibody or control preimmune serum diluted in PBS/1%  normal 
goat serum for 2 h at 37°C (1:2,000  dilution for Ab39, and 1:1,000 dilution 
for LT-2 and type I  collagen antibodies).  For detection an immunocy- 
tochemistry kit (Vectastain ABC-elite; Vector Laboratories, Inc., Burlin- 
game, CA) for rabbit IgG was used in combination with a DAB peroxi- 
dase substrate kit (brown reaction product) according to manufacturer's 
instructions (Vector Laboratories, Inc.). Some preparations were counter- 
stained for 2 rain with 1% methyl green before mounting. Other prepara- 
tions were also counterstained with alkaline phosphatase using an alkaline 
phosphatase substrate kit (red reaction product)  according to manufac- 
turer's instructions (Vector Laboratories, Inc.). Cell culture preparations 
were mounted in aqueous mounting medium according to manufacturer's 
instructions (Crystal mount; Biomedia Corp., Foster City, CA). Cryostat 
tissue sections were dehydrated through graded alcohols and mounted in 
mounting medium (DPX; Fluka Chemika, Buchs, Switzerland). Specific- 
ity of immunostaining for LTBP was confirmed by preincubating the im- 
mune serum for 30 min with partially purified human platelet latent TGF-13 
(230 kD) or recombinant human LTBP (kindly donated by K. Takemura). 
For immunofluorescent staining a biotinylated goat anti-rabbit second 
antibody (Vector Laboratories, Inc.) was used in conjunction with strepta- 
vidin-FITC (Pierce, Rockford, IL). The preparations were then viewed on 
a  confocal laser scanning microscope (LSM 10; Carl Zeiss Inc., Thoru- 
wood, NY). Fiber sizes were measured by image analysis. 
Treatment of  Fetal Rat Calvarial Cell Preparations 
with Plasmin 
For immunohistochemical analysis of fetal rat calvarial cell cultures after 
plasmin treatment, the cells were grown on Lab-tek chamber slides as de- 
scribed above until the early stage of differentiation, where the cells had 
reached confluence and LTBP fibrillar staining was well developed (see 
Fig. 2). The cells were washed twice in PBS and incubated with plasmin 
(0.1  U/ml) in serum-free a-MEM medium for 1 h at 37°C.  After incuba- 
tion with plasmin the cell cultures were fixed and stained for LTBP by im- 
munocytochemistry as described above. 
For Western blot analysis of plasmin-released latent TGF-[3 complexes, 
fetal rat calvarial cells were grown in six-well plates until the early stage of 
differentiation. The cells were then washed twice in PBS and lysed in ice- 
cold RIPA buffer (50 mM Tris-HC1, pH 7.2,  150 mM NaC1,  1% NP-40, 
0.5%  sodium deoxycholate).  The  deoxycbolate-insoluble pellet  (which 
consists predominantly of matrix proteins) was collected by centrifugation 
at 14,000 rpm for 10 min. The pellet was washed twice in PBS, and then di- 
gested with plasmin (0.1  U/ml) in serum-free a-MEM medium for 1 h. 
Proteins released by plasmin digestion were concentrated by precipitation 
in 80%  ethanol.  The protein pellet was then dissolved in nonreducing 
sample buffer, heated at 95°C for 5 min, and analyzed by SDS-PAGE fol- 
lowed by Western blotting. 
Western Blot Analysis of Plasmin-released Latent 
TGF-fl Complexes 
Proteins released by plasmin digestion of extracellular matrices were ana- 
lyzed by SDS-PAGE using 5-12%  gradient polyacrylamide gels as de- 
scribed previously (Bonewald et al., 1991; Dallas et al., 1994). The samples 
were run under nonreducing conditions (to keep the latent complexes in- 
tact). Proteins were then transferred onto a nitrocellulose membrane by 
electroblotting as described previously (Bonewald et al., 1991;  Dallas et 
al., 1994).  Membranes were blocked in 5% nonfat milk in TBS buffer (50 
mM Tris-HCl, 150 mM NaC1, pH 7.4) for 2 h at room temperature, and 
then incubated with either a  rabbit polyclonal antiserum against LTBP 
(Ab39), a rabbit polyclonal antibody against mature TGF-[3 (R & D Sys- 
tems, Inc.), or control nonimmune antiserum. Antibody incubations were 
carried out in TBS buffer +  5% BSA. Immunostained bands were visual- 
ized using peroxidase-conjugated protein-A (Kirkegaard & Perry Labora- 
tories, Inc., Gaithersburg, MD) in conjunction with the enhanced chemilu- 
minescence detection system used according to manufacturer's instructions 
(Amersham Corp., Arlington Heights, IL). 
Measurement of LTBP by ELISA 
A single-sided ELISA was used to measure LTBP concentrations in con- 
ditioned media from fetal rat calvarial cell cultures treated with sense and 
antisense oligonucleotides  against LTBP.  This ELISA  has a  detection 
limit of 10-20 ng/ml LTBP. High protein-binding EIA/RIA 96-well plates 
(Costar Corp., Cambridge, MA) were coated overnight with test samples 
or  recombinant LTBP standards diluted in PBS.  Background blocking 
was performed for 2 h at 37°C in PBS/5% BSA. The plates were then incu- 
bated with antiserum against LTBP (Ab39, 1:1,000  dilution in PBS/0.5% 
BSA) for 1 h  at 37°C. The detection antibody was an HRP-conjugated 
goat anti-rabbit antibody (Sigma Chemical Co.). O-phenylenediamine di- 
hydrochloride tablets (Sigma Chemical Co.) were  used as the reaction 
substrate  according  to  manufacturer's  instructions.  The  reaction  was 
stopped by the addition of 3 M HCl (25 p~l/100 Ixl reaction vol). The absor- 
bance at 492 nm was read, and LTBP concentrations in test samples calcu- 
lated by linear regression using the Immunofit EIA/RIA program, version 
3.00 (Beckman Instruments Inc., Fullerton, CA). 
Results 
Immunolocalization of LTBP in Fetal Rat 
Calvarial Cells 
LTBP staining was cytoplasmic in subconfluent, proliferat- 
ing fetal rat calvarial cultures (Fig. 2 A). Two days after 
the cells became confluent, LTBP staining was no longer 
cytoplasmic, but was localized in large fibrillar structures 
in the extracellular matrix, which appeared to form an or- 
ganized network throughout the culture (Fig. 2 B). As the 
cultures began to differentiate and cellular nodules began 
to form by days five through eight of culture, the LTBP 
fibrillar  structures  appeared  organized  around  and  be- 
tween the nodules and actually appeared to span between 
nodules, linking them together (Fig. 2 C). This pattern of 
staining was maintained in the cultures when the nodules 
had become mineralized after 9-16 d of culture (Fig. 2 D). 
Specificity of the antibody was confirmed by preincubat- 
ing the antibody with an excess of partially purified plate- 
let-derived latent TGF-13 or recombinant LTBP (data not 
shown). These controls appeared identical to the preim- 
mune controls shown in Fig. 2, E-H. 
Confocal immunofluorescent depth profiles through the 
developing nodules, such as the example shown in Fig. 2 I, 
revealed that the LTBP fibers were located almost exclu- 
sively in the cell layers at the bottom of the nodule, and 
did not penetrate the cell layers higher in the nodule. Thus 
it appeared that the bone nodule formed on top of the cell 
layer containing an organized network of LTBP fibers. 
LTBP Immunolocalization in Adult Rat Bone 
In the young adult rat ulna, LTBP expression was found in 
a  zone encircling the  whole circumference of the  bone. 
This corresponds to the fibrous periosteum, the layer of 
cells peripheral to the  alkaline  phosphatase-positive  os- 
teoblastic layer (Fig. 3 A). The staining was fibrillar, al- 
though here the fibers are in cross section. The fibrillar na- 
ture of the LTBP staining is more clearly demonstrated in 
the  connective tissue  of the  interosseous  ligament  that 
runs between the radius and ulna (Fig. 4, B  and C) from 
which measurements of the fiber sizes were made using 
image analysis. 
LTBP Staining in Fetal Rat Long Bones 
Fig. 3 C shows an oblique cryostat section through the de- 
Dallas et al. Latent TGF-[3-binding Protein Is a Matrix Protein  541 Figure 2. Immunolocalization  of LTBP (brown immunoperoxidase staining with methyl green counterstain) in long-term cultures of fe- 
tal rat calvarial cells using a polyclonal antiserum against LTBP (A-D) with preimmune serum controls (E-H). Bar, 100 txm. (A) Prolif- 
erating fetal rat calvarial cell cultures showing cytoplasmic localization of LTBP. (B) 2 d after reaching confluence (early stage) LTBP is 
localized to large fibrillar structures which form an organized network throughout the cultures. (C) 8 d after reaching confluence (mid- 
dle stage) the fetal rat calvarial cell cultures are forming multilayered cellular nodules. The large fibrillar structures which stain posi- 
tively for LTBP are organized around and between the developing nodules. (D) 15 d after reaching confluence the cellular nodules have 
become mineralized (late stage). The organization of LTBP-positive fibers spanning between mineralized nodules is maintained. (E-H) 
Preimmune serum controls for (A-D), respectively. (/) Confocal immunofluorescence  depth profile through a developing nodule from a 
fetal rat calvarial cell culture at the middle stage stained for LTBP. Color scale indicates the distance of each structure from the surface 
of the culture plate (blue) to the top of the nodule (red). Bar, 50 Ixm. 
The Journal  of Cell Biology,  Volume 131, 1995  542 Figure 3. Immunolocalization  of LTBP in the ulnae of young adult rats and the tibiae and metatarsals of 19-d fetal rats using a polyclonal 
antiserum against LTBP (A, C, E) with preimmune serum controls (B, D, F). Immunoperoxidase staining for LTBP (brown) with alka- 
line phosphatase histochemical stain (red) and methyl green nuclear counterstain. Bar, 100 ~tm. (A) LTBP staining (black arrows) sur- 
rounding a transverse section of a young adult rat ulna. Staining is present in the fibrous periosteum peripheral to the alkaline phos- 
phatase-positive osteoblast layer (white arrows). Staining is fibrillar, although here the fibers are in cross section. (B) Preimmune serum 
control, serial section to A. (C) oblique section of a 19 d fetal rat tibia showing LTBP staining (black arrows) adjacent to the alkaline 
phosphatase positive layer (white arrows) of the developing periosteum. (D) Preimmune serum control, serial section to C. (E) LTBP 
staining completely surrounds and delineates the developing metatarsals in this section of a 19-d fetal rat limb and extends into the car- 
tilaginous matrix. (F) Preimmune control, serial section to E. 
veloping tibia of a  19-d fetal rat. LTBP staining was local- 
ized in the developing periosteum in the layer of cells adja- 
cent to the alkaline phosphatase-positive osteoblast layer, 
similar to the staining pattern in the young adult rat. There 
was a  small zone of overlap where the cells were positive 
for  both  LTBP  and  alkaline phosphatase.  In developing 
fetal rat metatarsals (Fig. 3  E) that had not yet begun to 
mineralize, LTBP staining completely surrounded and de- 
lineated the developing cartilaginous bone rudiments. At 
higher magnification it could be seen that LTBP staining 
also extended partway into the cartilage matrix in certain 
areas  (data  not  shown).  There  was  evidence  of fibrillar 
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the fibrillar nature of the LTBP staining was most evident 
in  the  interosseus  ligament that connects  the  radius  and 
ulna (Fig. 4 B). Fiber measurements made from this region 
indicated that the fibers ranged from 0.7 to 1.3  }xm in di- 
ameter,  which  was  almost an  identical  size  to  the  fiber 
sizes measured in vitro. 
Figure 4. (A) Confocal immunofluorescence  micrograph showing 
examples of LTBP fibrillar structures  in a confluent  fetal rat cal- 
varial cell culture which were measured using image analysis, Fi- 
ber sizes ranged from 0.6-1.2  ~m in diameter. Bar, 10 ixm. (B) 
Immunoperoxidase staining of LTBP fibrillar structures  (arrows) 
in the interosseous ligament between the radius and ulna of a young 
adult rat. Bar, 100 Ixm.  (C) Higher power computer enhanced  im- 
age showing examples of fibers measured by image analysis. Fi- 
ber sizes ranged from 0.7-1.3 ~m in diameter.  Bar, 10 Ixm. 
staining  in  some  areas,  but  the  fibrillar  staining  pattern 
was not as well developed as in the young adult rat. 
Size Measurement of  LTBP Fibrillar Structures 
The LTBP fibrillar structures in fetal rat calvarial cell cul- 
tures were measured by image analysis using confocal im- 
munofluorescence  microscopy (Fig.  4  A).  Fibers  ranged 
Immunolocalization of TGF-fll Precursor and Type I 
Collagen in Fetal Rat Calvarial Cells 
Immunostaining  for TGF-131  precursor  also  revealed  fi- 
briUar structures in the extracellular matrix of postconflu- 
ent cultures of fetal rat calvarial cells (Fig. 5 B). Although 
the fibrillar staining with anti-TGF-131 precursor was not 
as  pronounced  as  with  anti-LTBP  (Fig.  5 A),  the  fibers 
were  of similar  size,  suggesting  that  the  LTBP  fibriUar 
structures probably had TGFq31 associated with them. In 
contrast, staining for type I collagen was distinctly differ- 
ent from that  seen with LTBP. At 2  d  after confluence, 
when  a  well-organized  network  of LTBP  fibers was  al- 
ready formed (Fig. 5 A), staining for type I  collagen was 
still predominantly cytoplasmic, with only a  few collagen 
fibers visible in  the  extracellular  matrix  (Fig.  5  C).  Col- 
lagen fibers were not abundant in the extracellular matrix 
until  the  middle  stage of differentiation  at ~5--6 d  after 
confluence. Thus the appearance of LTBP fibrillar struc- 
tures in the extracellular matrix preceded the appearance 
of type I collagen fibers. 
Effect of Plasmin Treatment on LTBP 
Immunostaining and Release of  Latent TGF-fl 
Complexes from the ExtraceUular Matrix of 
Fetal Rat Calvarial Cells 
Taipale et al. (1994)  have reported previously that LTBP 
is  covalently linked  to  the  extracellular  matrix of fibro- 
blasts,  but  that  latent  TGF-13  complexes containing  pro- 
teolytic fragments of LTBP are released by digestion with 
plasmin. In the present study, treatment of fetal rat calva- 
rial  cell  cultures  with  plasmin  (0.1  U/ml)  abolished  the 
fibrillar staining for LTBP in the extracellular matrix (see 
Fig. 6, A  and B). Disappearance of the flbrillar staining co- 
incided  with the release of both LTBP and TGF-[3 from 
the  extracellular matrix of fetal rat calvarial cells. These 
were  present  in  a  high  molecular  weight  latent  TGF-[3 
complex which migrated slightly greater than 200-kD un- 
der nonreducing conditions (see Fig. 6 C). This agrees well 
with the band sizes reported by Taipale et al. (1994),  and 
probably represents a high molecular weight latent TGF-[3 
complex consisting of the 100-kD precursor form of latent 
TGF-I3 complexed to an ,-~120-kD  proteolytic fragment of 
LTBP. A  higher molecular weight doublet was also seen 
with  anti-LTBP  antibodies  which  may  represent  aggre- 
gates of LTBP molecules. Antibodies to TGF-I3 appeared 
to  recognize  only the  lower band  of the  high  molecular 
weight doublet, indicating that this form also had TGF-13 
associated with it.  Consistent with the Western blot data, 
plasmin treatment of fetal rat calvarial cell cultures  also 
resulted in an increase in the amount of latent TGF-[3 de- 
tectable in the conditioned medium by bioassay (data not 
shown). 
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(A) LTBP,  (B) TGF-[31-precur- 
sor, (C) type I  collagen in fetal 
rat  calvarila cell cultures  com- 
pared with (D)  nonimmune se- 
rum control. Immunoperoxidase 
staining was performed with no 
counterstain. Bar,  100  t~m. (A) 
LTBP  fibrillar  structures  are 
present  in  a  well-formed  net- 
work by 2 d  after confluence in 
early fetal rat calvarial cell cul- 
tures. (B) TGF-[31  precursor lo- 
calizes to  similar fibrillar struc- 
tures in the extracellular matrix. 
(C)  type  I  collagen staining  is 
still predominantly cytoplasmic 
at this stage of culture, with only 
a  few collagen fibers present in 
the  extracellular  matrix.  Col- 
lagen fibers are not abundant in 
the extracellular matrix until day 
5-6  after confluence.  (D)  Non- 
immune control. 
Effect of  Antibodies and Antisense 
Oligonucleotides to LTBP on Bone Nodule Formation 
in Fetal Rat Calvarial Cell Cultures 
To determine whether the LTBP fibrillar structures played 
any role in the formation of mineralized bone nodules in 
fetal rat  calvarial cell cultures,  the  cultures were  treated 
with  antibodies  or  antisense  oligonucleotides  directed 
against  LTBP.  When  antibodies  to  LTBP  were  added 
throughout  the  12-d  culture  period  they  inhibited  bone 
nodule formation in a  dose-dependent manner  (Fig. 7, A 
and B). Both the number and size of the bone nodules was 
inhibited.  Antisense  oligonucleotides against LTBP  also 
inhibited bone  nodule formation moderately, but signifi- 
cantly, compared with control sense oligonucleotides (Fig. 
7,  C  and D). When conditioned media samples were col- 
lected after 3 d of treatment, antisense oligonucleotides to 
Figure  6.  (A  and  B)  Immu- 
nolocalization of  LTBP  and 
(C)  Western blot  analysis of 
LTBP and TGF-13 after treat- 
ment of fetal rat calvarial cell 
cultures  with  0.1  U/ml  plas- 
min. Immunoperoxidase stain- 
ing  was  performed  with  no 
counterstain. Bar, 100 Ixm. (A) 
Control  culture  stained  with 
anti-LTBP  showing  fibrillar 
staining  pattern,  (B)  culture 
treated with 0.1 U/ml plasmin 
for 1 h then stained with anti- 
LTBP. Fibrillar  staining is abolished, (C) Western blot analysis of latent TGF-13 complexes released by plasmin treatment of the extracellular 
matrix from fetal rat calvarial cells (nonreducing gel). A complex slightly greater than 200 kD is seen (arrow) which reacts with both anti- 
LTBP and anti-TGF-13 antibodies. 
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serum  (A  and  B)  and  antisense  oligonucleotides  (C  and  D) 
against  LTBP on the number and area of mineralized  nodules 
formed in long term cultures of fetal rat calvarial cells. *, signifi- 
cantly  decreased compared with  preimmune serum control  or 
sense oligonucleotide  control. P  <  0.05 (ANOVA/student-New- 
man-Keul's method of multiple comparisons).  (A and B) I-q,  con- 
trol; II, anti-LTBP; and [], nonimmune. (C and D) El, control; II, 
LTBP-antisense;  and [], LTBP-sense. 
LTBP at the 5-1xM dose were found to reduce significantly 
the amount of LTBP protein secreted by the cells as mea- 
sured by ELISA (see Table I). Other supportive data for a 
role for LTBP in bone formation in vitro includes reduc- 
tion of the number and size of mineralized bone nodules 
formed in cultures of fetal rat calvarial cells treated with 
plasmin, which releases LTBP from the extracellular ma- 
trix (data not shown). 
To determine whether active TGF-13 was also playing a 
role in bone nodule formation in vitro, fetal rat calvarial 
cell cultures were treated with antibodies to TGF-131  and 
TGF-132. These antibodies had essentially no effect on ei- 
ther the number or size of the nodules (data not shown). 
This suggests that, in contrast to LTBP, active TGF-13 does 
not play a significant role in bone formation in vitro. 
Table I. Concentrations of LTBP in Conditioned Media from 
Fetal Rat Calvarial Cell Cultures Treated with Sense and 
Antisense Oligonucleotides against LTBP (as shown in Fig.  7, 
C and D) 
LTBP concentration 
Control 
LTBP sense 
LTBP antisense 
ng/ml 
196.1 _+ 11,2 
5.0 I~M  176.9 _+ 1.3 
0.5 ixM  165.0 + 2.0 
5.0 txM  81.1 _+ 3.9* 
0.5 txM  186.9 _+ 7.6 
Data are mean -  SEM from triplicate wells. 
* Significantly decreased compared with sense control,  P  <  0.05  (ANOVA/student- 
Newman-Keul's method of multiple comparisons). 
Discussion 
In this study we have clearly demonstrated that LTBP lo- 
calizes to large (0.6-1.3  ~m) fibrillar structures in the ex- 
tracellular matrix of bone  cells in  vitro and  in  vivo. Al- 
though these observations are entirely consistent with the 
hypothesis that LTBP targets latent TGF-13  to the  extra- 
cellular matrix for storage, they also suggest a previously 
undescribed role for this protein as a structural extracellu- 
lar  matrix  protein.  The  fibrillar localization  of LTBP  is 
particularly interesting in view of the homology of LTBP 
to the fibrillins. Fibrillins 1 and 2 have been identified, and 
a fibrillin-like protein has also been reported (Sakai et al., 
1986,  1991;  Rosenbloom et al.,  1993;  Zhang et al.,  1994). 
These proteins are a  major component of connective tis- 
sue microfibrils and share a number of features with LTBP 
including multiple EGF-like repeats, an RGD sequence, a 
putative  calcium-binding  domain,  and  a  novel eight-cys- 
teine  repeat motif which is unique  to this family of pro- 
teins. This suggests that there may be a whole gene family 
of fibrillin-like proteins that are involved in the formation 
of microfibrils and that have important structural roles in 
maintaining tissue integrity and organization. 
A  number of other unrelated proteins have been shown 
to be constituents  of microfibrils. These include  a  78-kD 
microfibrillar protein (MP78)  and a  31-kD protein called 
microfibril-associated glycoprotein  (Gibson et  al.,  1989). 
In some tissues, microfibrils may be associated with elastin 
to form elastic fibers (for review see  Rosenbloom et al., 
1993) and a recent report has shown that the proteoglycan 
versican  is  associated  with  elastic  fibers  in  the  dermis 
(Zimmerman et al., 1994). Thus it appears that microfibrils 
may be  composed  of a  number  of constituent  proteins, 
whose relative proportions vary in different tissues,  thus 
defining  structural  and  functional  characteristics  specific 
for each tissue (Davis, 1994).  A  second latent TGF-[3 bind- 
ing protein (LTBP-2) recently has been isolated which has 
41% homology of LTBP (Mor6n et al., 1994)  and it seems 
probable that  the  LTBPs will be classified as new mem- 
bers  of  the  growing  family  of  fibrillin-like  proteins  in- 
volved in the  formation of connective tissue microfibrils. 
This hypothesis is currently under investigation in our lab- 
oratory and  preliminary data  indicate  that,  like  fibrillin, 
some of the LTBP fibrillar structures colocalize with elas- 
tic fibers in the young adult rat ulna, but that other LTBP 
fibers exist independently of any elastin (Dallas, S. L., un- 
published observations). 
The  fibrillar localization  of LTBP in  the  extracellular 
matrix of bone cells is clearly consistent with a role for this 
molecule in storing latent TGF-[3 in the matrix. This idea is 
supported  by the  finding  that  immunostaining for TGF- 
[M-precursor reveals similar fibrillar structures in the ex- 
tracellular matrix of fetal rat calvarial cells. Furthermore, 
the demonstration that loss of fibrillar LTBP staining after 
treatment with plasmin is associated with release of both 
LTBP  and  TGF-13  in  a  high  molecular  weight  complex 
provides further  evidence that  the  LTBP fibers do  have 
TGF-13 associated with them. 
Our data support those of Taipale et al. (1994) showing 
that LTBP complexed to TGF-[~ can be released from the 
extracellular  matrix of fibroblasts by plasmin  treatment. 
This finding may be very significant in view of the poten- 
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established that plasmin is able to activate the precursor 
form of latent TGF-[3 in the test tube (Lyons et al., 1988; 
1990).  The  plasminogen-plasminogen  activator  system 
may also be involved in the activation of latent TGF-13 ob- 
served  in  co-cultures  of endothelial  and  smooth  muscle 
cells (Sato and Rifkin, 1989) and in osteoblasts stimulated 
by parathyroid hormone (Yee et al., 1993).  Expression of 
plasminogen activator is regulated by numerous agents, in- 
cluding  osteotropic factors such as parathyroid  hormone 
(Hamilton et al., 1985; Pfeilschifter et al., 1990; Yee et al., 
1994).  Therefore the plasminogen-plasminogen activator 
system may mediate the effects of agents such as parathy- 
roid hormone on TGF-[3 activity. The observations of the 
present study together with those of Taipale et al. (1994) 
indicate  that plasmin is able not only to activate soluble 
forms of latent TGF-13,  but is also able to access matrix- 
bound stores of latent TGF-[3 through cleavage of LTBP. 
This may have important  consequences  for tissue  repair 
and  wound  healing,  and  release  of matrix-bound  latent 
TGF-13 may be one of the mechanisms through which plas- 
min exerts its effects on matrix remodeling. 
In  nodule-forming  fetal  rat  calvarial  cell  cultures  the 
LTBP fibrillar structures were located in the cell layers un- 
derneath the bone nodule. In vivo LTBP was found in an 
analogous distribution, surrounding the bone and adjacent 
to the alkaline phosphatase-positive bone forming osteo- 
blasts. These observations, together with the evidence that 
antibodies  and  antisense  oligonucleotides  against  LTBP 
inhibited nodule formation, indicate that formation of the 
LTBP fibrillar structures may be an important event for 
subsequent bone formation to occur. It seems unlikely that 
this is a process specific to bone cells, but rather that the 
LTBP flbrillar structures  are involved in maintaining the 
structural integrity of the tissue or cell monolayer, which 
may be a prerequisite for bone formation to occur. Thus, 
the LTBP fibers may form a "scaffolding" upon which the 
bone subsequently forms. An alternative possibility is that 
the LTBP fibrillar structures are involved in cell migration 
and organization,  and  that the  arrangement of LTBP fi- 
bers may determine where bone will form. These hypothe- 
ses are currently under investigation. 
It is well documented that TGF-13  autoinduces its own 
mRNA expression in several cell types (Van Obberghen- 
Schilling et al., 1988; Bascom et al., 1989; Kim et al., 1989, 
1990). TGF-[3 has also been shown to stimulate expression 
of numerous matrix proteins that include fibronectin and 
the fibronectin receptor, collagen, elastin, tenascin, throm- 
bospondin,  biglycan,  and  vitronectin  (Ignotz  and  Mas- 
sagu6,  1986;  Penttinen  et  al.,  1988;  Roberts et  al.,  1988; 
Rossi et al., 1988; McKay et al., 1993; Marigo et al., 1994). 
We have shown previously that TGF-I3 is able to stimulate 
expression  of mRNA  and  protein  for  both  TGF-13  and 
LTBP in osteosarcoma cells (Dallas et al., 1994) and have 
recently confirmed a similar effect in subconfluent fetal rat 
calvarial  cells  (Dallas,  S.  L.,  unpublished  observations). 
The addition  of LTBP to the  list of extracellular  matrix 
proteins whose expression is stimulated by TGF-[3 further 
emphasizes the  importance  of this  molecule  in  inducing 
new extracellular matrix formation. TGF-13 also promotes 
matrix  accumulation  by inhibiting  the  expression  of the 
proteases that might degrade matrix proteins while stimu- 
lating  expression  of protease  inhibitors  (Edwards  et  al., 
1987;  Laiho et al., 1987;  Kubota et al., 1991; Tomooka et 
al.,  1992).  Thus TGF-[3 promotes extracellular matrix ac- 
cumulation by exerting control at multiple levels. The in- 
corporation of latent TGF-[3 into the matrix through bind- 
ing to LTBP may represent  another level of control for 
TGF-13, whereby it can exert effects on cells at a later date 
• after release from the matrix and  subsequent  activation. 
This may be particularly important in tissue repair, where 
TGF-13  appears  to  play  a  pivotal  role  in  determining 
whether  healing  will be normal as in  wound  healing,  or 
pathological as in scarring and fibrotic diseases. 
An interesting finding was that in fetal rat calvarial cell 
cultures,  a  well-organized  network  of LTBP  fibers  was 
clearly visible by two days after confluence, which is well 
before type I collagen fibers became abundant in the ex- 
tracellular matrix at five to six days after confluence. Al- 
though this does not rule out the possibility that the fibril- 
lar LTBP staining occurs as a result of its binding to other 
fibrillar matrix protein(s), such as the fibrillins or fibronec- 
tin, it does indicate that LTBP is not colocalizing with type 
I collagen, the most abundant matrix protein in bone. The 
fact that the LTBP fibrillar staining precedes the appear- 
ance of collagen fibers in the extracellular matrix suggests 
that it may be one of the earliest proteins to appear in the 
matrix.  Preliminary  data  in  our laboratory indicate  that 
LTBP  expression  is  increased  in  certain  fibrotic  disease 
states. Therefore an understanding of the mechanisms for 
regulation of LTBP expression may be of great clinical im- 
portance  in  treating  fibrotic  disease  states,  particularly 
since  excess  TGF-13  may play a  major causative role  in 
these conditions (Border et al., 1992). 
In conclusion, this study is the first demonstration that 
the latent TGF-[3 binding protein is a structural extracellu- 
lar matrix protein involved in the formation of large fibril- 
lar  structures  in  the  extracellular  matrix  of  bone  cells• 
LTBP appears to play a  role in bone formation in vitro 
and its localization in vivo is also suggestive of a  role in 
bone development and formation. Future  studies  are re- 
quired to elucidate further the role of this protein in bone 
formation, particularly in view of recent reports that Mar- 
fan syndrome and related disorders of the cardiovascular 
and skeletal systems have been linked to mutations in genes 
for the fibrillin family of extracellular matrix proteins of 
which LTBP may be a new member (Dietz et al., 1991; Lee 
et al., 1991; Maslen et al., 1991; Milewicz et al., 1992; L6nn- 
qvist et al.,  1994).  TGF-13  may be the first example of a 
growth factor whose latent form is complexed to a protein 
which  actually appears to function  as a  structural  matrix 
protein, and may play a role in both storage of the mole- 
cule in the matrix and its subsequent release and activa- 
tion.  This  may be a  precedent for other growth  factors, 
and could represent an exquisite system for the fine regu- 
lation of growth factor actions. 
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